Replimune Inc.

This is an early-stage safety study testing a new treatment called RP2, which is a genetically modified cold sore virus designed to kill cancer cells and boost the immune system. It is being given alone and in combination with an existing immunotherapy drug (nivolumab) to adults …

This early-stage study is testing a new treatment called RP3, which is a genetically modified virus designed to attack cancer cells and boost the immune system. It will be given to about 123 adults with advanced solid tumors that have not responded to standard treatments, both by…

This study is testing an experimental virus therapy called RP1, both alone and combined with an immunotherapy drug (nivolumab), for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find the safest and most effective dose whi…

This program provided early access to an experimental treatment combining a modified virus (VO) with an existing immunotherapy drug (nivolumab) for adults with advanced skin cancer (melanoma) that had worsened despite standard treatment. The goal was to see if the virus could hel…